
    
      The study is a randomized, double blind, multicenter, placebo controlled, parallel group,
      proof of concept study comparing the efficacy, safety, and acceptability of 3 doses of
      S-equol to placebo in menopausal patients with vasomotor symptoms. The study objective is an
      evaluation of the dose response of 3 dose levels of AUS-131 (S-equol) and placebo with
      respect to reducing the mean number of moderate to severe vasomotor symptoms after 4 weeks of
      treatment. The safety of S-equol will be evaluated during the study.
    
  